Sanofi SA (SAN) Given a €81.00 Price Target at HSBC Holdings plc
Several other equities research analysts have also commented on SAN. UBS AG set a €82.00 ($97.62) price objective on Sanofi SA and gave the stock a neutral rating in a research note on Wednesday, June 14th. J P Morgan Chase & Co restated a neutral rating and issued a price objective on shares of Sanofi SA in a research note on Friday, September 8th. Kepler Capital Markets set a €90.00 ($107.14) price objective on Sanofi SA and gave the stock a buy rating in a research note on Thursday, September 7th. Goldman Sachs Group, Inc. (The) set a €82.00 ($97.62) price objective on Sanofi SA and gave the stock a neutral rating in a research note on Tuesday, August 1st. Finally, BNP Paribas set a €85.00 ($101.19) price objective on Sanofi SA and gave the stock a neutral rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the stock. Sanofi SA presently has an average rating of Hold and an average target price of €88.19 ($104.99).
Sanofi SA (SAN) opened at 81.85 on Tuesday. The stock has a 50 day moving average price of €26.12 and a 200-day moving average price of €25.98. The company has a market capitalization of €102.78 billion and a price-to-earnings ratio of 11.42. Sanofi SA has a 12-month low of €24.55 and a 12-month high of €82.03.
ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/13/sanofi-sa-san-given-a-81-00-price-target-at-hsbc-holdings-plc.html.
Sanofi SA Company Profile
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.